Lilly To Give High-Risk Alzheimer’s Drug “Every Chance,” Lechleiter Says At JP Morgan
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly is relying heavily on biomarkers to help its Alzheimer’s disease-modifying drug solanezumab progress, executives tell a crowd of analysts at JP Morgan. Though the project is high risk, Lechleiter pointed to the company’s full pipeline and success of diabetes portfolio as signs of Lilly’s momentum.
You may also be interested in...
Bristol Opens A Phase III Door Into Gamma Secretase As Lilly Closes Another
Whether Bristol-Myers Squibb Co. and others can succeed at bringing a gamma secretase inhibitor to market for the treatment of Alzheimer's disease is far from certain.
Making The Most Of ACOs: How Biopharma Is Adapting To New Customer Segment
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?
Building Long-Term Value Into Near-Term Commercial Strategy
Pharma companies are building long-term value propositions that should appeal to Accountable Care Organizations into some go-to-market strategies for new drugs and to repositioning efforts of already marketed drugs that have hit snags. The rationale might seem straightforward—for example, more convenient dosing that improves compliance and cuts down hospitalization rates--but the nuances can be complex. Moreover, even when their products appear to have compelling cases for value, companies have not by and large made ACOs a distinct target for their commercial operations.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: